華蘭生物(002007.SZ):控股子公司華蘭疫苗創業板IPO過會
格隆匯8月26日丨華蘭生物(002007.SZ)宣佈,根據深交所創業板發行上市審核信息公開網站公吿,2021年8月25日,深交所創業板上市委員會召開2021年第51次上市委員會審議會議,對公司控股子公司華蘭生物疫苗股份有限公司(簡稱“華蘭疫苗”)首次公開發行股票申請進行了審議。根據會議審議結果,華蘭疫苗首發符合發行條件、上市條件和信息披露要求。
華蘭疫苗成立於2005年,是一家從事疫苗的研發、生產和銷售的高新技術企業。2020年6月,華蘭疫苗完成股份改制,設立股份有限公司,總股本3.6億股,公司持有華蘭疫苗2.7億股,佔其發行前總股本的75%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.